MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:34Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antimalarials]]
			[[Category:DMARDs]]
			[[Category:Immunomodulators]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #131

2026-05-23T03:51:55Z

parser-claude batch MedTemplate pre-fill, Top 300 #131

New page

{{MedTemplate
| generic = Hydroxychloroquine
| brand = Plaquenil; mostly prescribed generically
| structure =
| classes = [[:Category:Antimalarials|Antimalarial (4-aminoquinoline)]], [[:Category:DMARDs|DMARD]], [[:Category:Immunomodulators|Immunomodulator]]
| uses = <vote slug="rheumatoid-arthritis-use">Rheumatoid arthritis</vote>, <vote slug="sle-use">Systemic lupus erythematosus</vote>, <vote slug="discoid-lupus-use">Discoid and subacute cutaneous lupus</vote>, <vote slug="sjogren-use">Sjögren's syndrome</vote>, <vote slug="malaria-use">Malaria treatment and prophylaxis (chloroquine-sensitive areas)</vote>
| starting_dose = 200-400 mg PO daily; '''dose by actual body weight ≤5 mg/kg/d''' to reduce retinopathy risk (AAO 2016 guideline)
| preparations = 200 mg tablets; 100 mg/5 mL suspension
| fda_max = 400 mg/d typical maintenance; weight-adjusted ceiling per ophthalmology guidance
| pill_id =
| routes = Oral
| onset = Rheumatologic effect at 6-12 weeks
| duration = Weeks (long half-life)
| halflife = ~40 days (terminal; reflects extensive tissue distribution)<ref name="plaquenil-label">FDA Prescribing Information, Plaquenil (hydroxychloroquine sulfate), Sanofi-Aventis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s048lbl.pdf</ref>
| bioavailability = 70-75% (oral)<ref name="plaquenil-label" />
| pregnancy = Long-considered safe in pregnancy for lupus and other rheumatologic indications; benefits typically outweigh.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="hydroxychloroquine-mech-claim">Hydroxychloroquine accumulates in lysosomes (lysosomotropic weak base), raising lysosomal pH and impairing endolysosomal antigen processing and TLR7/9 endosomal signaling; the net effect dampens innate immune activation and reduces autoantibody production in lupus and inflammation in rheumatoid arthritis.</vote> '''Retinal toxicity''' is the dose- and duration-limiting adverse effect (bull's eye maculopathy with photoreceptor damage); the 2016 American Academy of Ophthalmology guideline established the ≤5 mg/kg actual-body-weight ceiling and baseline + annual screening starting at year 5<ref name="plaquenil-label" />. QT prolongation and rare cardiomyopathy are recognized cardiac risks. The 2020 COVID-19 controversy is documented separately; HCQ does not have established benefit in COVID-19 and was eventually withdrawn from active recommendation.
}}

== References ==
<references />

Hydroxychloroquine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #131